Abstract-The calcineurin inhibitor cyclosporine A (CsA) suppresses the immune system but promotes hypertension, vascular dysfunction, and renal damage. CsA decreases regulatory T cells and this contributes to the development of hypertension. However, CsA's effects on another important regulatory immune cell subset, myeloid-derived suppressor cells (MDSCs), is unknown. We hypothesized that augmenting MDSCs would ameliorate the CsA-induced hypertension and vascular and renal injury and dysfunction and that CsA reduces MDSCs in mice. Daily interleukin-33 treatment, which increased MDSC levels, completely prevented CsA-induced hypertension and vascular and renal toxicity. Adoptive transfer of MDSCs from control mice into CsA-treated mice after hypertension was established dose-dependently reduced blood pressure and vascular and glomerular injury. CsA treatment of aortas and kidneys isolated from control mice for 24 hours decreased relaxation responses and increased inflammation, respectively, and these effects were prevented by the presence of MDSCs.
C yclosporine A (CsA) still remains one of the primary chronic immunosuppressive drugs for use in patients with focal segmental glomerulosclerosis, membranous nephropathy, psoriasis, rheumatoid arthritis, and other autoimmune diseases despite the known potential cardiovascular and renal side effects. 1 Numerous studies have reported mechanisms by which CsA promotes hypertension and vascular and renal toxicity, including increased sympathetic nerve activity and decreased vascular relaxation. [2] [3] [4] [5] [6] [7] Significantly safer immunosuppressive drugs are on the way, but until they are routinely used in the clinic, ways to reduce the detrimental cardiovascular and renal effects of CsA are needed.
One of the mechanisms by which CsA causes hypertension and cardiorenal toxicity is by altering immune cell subsets. We and others have reported that CsA decreases antiinflammatory and tolerogenic regulatory T cells (Tregs), but increases interleukin (IL)-17-producing T cells, which contribute to the development of hypertension, as we recently reported that augmenting Tregs or neutralizing IL-17 normalized blood pressure and prevented vascular and renal injury in CsA-treated mice. [8] [9] [10] [11] [12] [13] [14] [15] [16] However, it is unknown whether CsA affects another anti-inflammatory regulatory immune cell, myeloid-derived suppressor cells (MDSCs).
MDSCs consist of immature myeloid cells that are precursors for granulocytes, macrophages, and dendritic cells. Their immunosuppressive function is mediated largely by an upregulation of arginase and inducible nitric oxide synthase (iNOS or NOS2), which leads to arginine catabolism and reactive oxygen species production and a subsequent decrease in T-cell proliferation. [17] [18] [19] [20] [21] [22] [23] MDSCs can secrete various anti-inflammatory cytokines including IL-4, IL-10, IL-13, and transforming growth factor, and are also reported to induce Tregs under certain conditions. [24] [25] [26] In conjunction with Tregs, MDSCs are the major regulatory immune cells that help quench immunity and inflammation. Shah et al 27 reported recently that MDSC levels increase in various mouse models of hypertension (angiotensin II, NOS inhibition, and high salt), similar to what is known to happen in other states of inflammation. Further augmenting MDSC levels by adoptive transfer was able to lower blood pressure in all hypertensive models, whereas depleting MDSCs exacerbated the inflammation and hypertension caused by angiotensin II. However, it is possible that inhibition of calcineurin by CsA reduces MDSC levels, similar to the effect it has on Tregs.
We utilized 2 strategies to determine whether augmenting MDSC levels would be effective in reducing CsA-induced organ injury and hypertension (1) exogenous IL-33 which is well known to increase MDSC levels 28, 29 and (2) MDSC adoptive transfer. We also determined whether CsA directly affects MDSCs. We hypothesized that treatment with either IL-33 or isolated MDSCs would attenuate the development of vascular and renal injury and hypertension induced by CsA in mice, and that calcineurin inhibition decreases MDSCs and this loss of a source of anti-inflammatory cytokines contributes to the end organ injury and hypertension caused by CsA.
Materials and Methods
Detailed Materials and Methods are available in the online-only Data Supplement.
Animals and Treatments
Male C57Bl/6J mice (Jackson Laboratory) aged 10 to 18 weeks were used for the CsA treatment studies. Systolic blood pressures were measured by tail-cuff (IITC, Inc) daily, at the same time each day, after 3 days of training. After blood pressure measures, mice were injected intraperitoneal with CsA (50 mg/kg per day; Alomone, Israel) or diluent (saline and DMSO, 0.2% final concentration) as described previously.
9,30-32 Some mice were also given daily intraperitoneal injections of IL-33 (0.5 µg/mouse per day; eBioscience). 28, 29 Other control and CsA-treated mice were injected intraperitoneal with primary MDSCs isolated from male control mice on days 1, 4, and 7. Male control mice were euthanized and MDSCs were isolated from the spleens and bone marrow according to the manufacturer's protocol (Miltenyi Biotech; No. 130-094-538).
Animals were anesthetized on day 8 with isoflurane and euthanized by cervical dislocation. All procedures were approved by the Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Serum Creatinine
Blood was obtained by cardiac puncture under anesthesia. Serum creatinine was measured according to the manufacturer's protocol (R&D Systems).
Vascular Reactivity
Vascular reactivity was measured in endothelium-intact aortas as described previously. [31] [32] [33] [34] Concentration-force curves were generated for the endothelium-dependent dilator acetylcholine and the endothelium-independent dilator sodium nitroprusside after contraction with an EC 70 concentration of phenylephrine.
Immunoblotting
For protein analyses from whole aortic and kidney tissue, tissue lysates were processed and total protein concentration was determined as described previously. 9 The blots were probed for fibronectin (Abcam), E-selectin (Abcam), collagen (Millipore), calcineurin (Cell Signaling), and β-actin (Sigma) and were identified simultaneously (800 nm and 700 nm wavelengths, respectively) using near-infrared visualization (Odyssey System, LI-COR Biosciences). Densitometry was performed using the Odyssey software.
Histology and Morphometric Analysis
Left kidney histological sections were prepared as described previously. 9 Three blinded investigators quantitated glomerular injury according to a scale described previously. 9 In brief, 15 glomeruli per tissue section were scored on a 0 to 4 scale, where 0=normal size, normal mesangium, and no congestion; 1=minimal hypertrophy, mesangial expansion, and congestion; 2=mild hypertrophy, mesangial expansion, and congestion; 3=moderate hypertrophy, mesangial expansion, and congestion; and 4=severe hypertrophy, mesangial expansion, and congestion. Mean glomerular injury index for each group was calculated by ( 
where N0-N4=number of glomeruli with scores of 0 to 4, respectively, as described previously.
9,35

Flow Cytometry
Spleens were harvested from the mice and single cell suspensions were generated as described previously. 9 One million cells from the spleen were stained with anti-mouse CD11b clone M1/70 (BD Pharmingen), anti-mouse Ly-6G and Ly6C clone RB6-8C5 (BD Pharmingen), or isotype controls for 1 hour at 4°C in the dark. Other splenocytes were stained with anti-mouse CD3e (BD Pharmingen), anti-mouse CD4 (BD Pharmingen), anti-mouse CD25 clone PC61.5 (eBioscience), or isotype controls. These cells were then fixed and permeabilized with the BD CytoFix/CytoPerm Fixation/Permeabilization Kit (BD Pharmingen) followed by intracellular staining using an anti-mouse FoxP3 antibody (eBioscience). Flow cytometry was performed on a BD FACS Canto II and analyzed using FlowJo. CD11b + lymphocytes were quantified and averaged as described previously.
9,32 Data were expressed as % of lymphocytes.
Isolated Aortas and Kidneys and Treatments
Aortas were excised from male control mice, cleaned of adipose tissue, and incubated with CsA (50 µmol/L) for 24 hours in the absence and presence of 75 000 MDSCs isolated from male control mice. Segments 2 mm in length were cut from the thoracic portion, mounted in a myograph, and vascular reactivity studies were performed as above, whereas the rest of the tissue was used for immunoblotting. Right kidneys isolated from the same control mice were treated with CsA (50 µmol/L) for 24 hours in the absence and presence of 75 000 MDSCs and then immunoblotting for fibronectin and actin were performed as above.
Microvascular and Glomerular Endothelial Cells and Treatments
Murine microvascular and glomerular endothelial cells were obtained from Cell Biologics and cultured according to the manufacturer's guidelines. Endothelial cells were treated with CsA (50 µmol/L) for 24 hours in the absence and presence of 75 000 MDSCs isolated from control mice. The cells were then processed for fibronectin immunoblotting as described above.
Isolated MDSCs and Treatments
MDSCs were isolated from male control mice spleens and bone marrow using the Miltenyi Biotech MDSC isolation kit. GM-CSF (granulocyte-macrophage colony-stimulating factor; 10 ng/mL; R&D Systems) was added to the cells for survival. MDSCs were incubated for 24 hours with different concentrations of CsA (0, 10, 25, and 50 µmol/L), the calcineurin autoinhibitory peptide (0, 10, 50 µmol/L; Calbiochem), or the selective nuclear factor of activated T cells (NFAT) inhibitor VIVIT (0, 10, and 25 µmol/L; Calbiochem) in the absence and presence of 75 000 MDSCs isolated from male control mice. The % of live MDSCs compared with 24-hour, DMSO vehicle-treated MDSCs were then determined by flow cytometry.
Statistical Analyses
Results are presented as mean+SEM. For multiple comparisons, either a 2-way ANOVA or a repeated measures 2-way ANOVA (main effects: group [Con or CsA] and treatment [Vehicle, IL-33, or MDSCs]) was used followed by the Student-Newman-Keuls post hoc test. The significance level was set at 0.05. All analyses were performed using SigmaStat 3.5 software.
Results
IL-33 Prevents CsA-Induced Hypertension and Vascular and Renal Toxicity
Daily CsA treatment significantly increased systolic blood pressure in mice ( Figure 1A ) and decreased acetylcholine-induced aortic relaxation responses ( Figure 1B) , while having no effect on sodium nitroprusside-induced relaxation responses ( Figure 1C ). Aortas and kidneys from CsA-treated hypertensive mice had significantly increased levels of the injury marker fibronectin ( Figure 1D ). Glomeruli from CsAtreated mice exhibited significantly more injury evidenced by hypertrophy, mesangial expansion, hypercellularity, and congestion ( Figure 1E ). Serum creatinine levels were also increased 2-fold in CsA-treated mice (Con=0.7014±0.0794, CsA=1.4174±0.0207; CsA P<0.05 versus Con). All of these effects were associated with a significant decrease in splenic MDSC levels ( Figure 1F ). The gating strategy for flow cytometry analysis of splenic MDSCs is presented in Figure S1 in the online-only Data Supplement, and representative dot plots for each group are presented in Figure S2 . To determine whether MDSC augmentation by IL-33 can prevent the development of CsA-induced organ injury and hypertension, daily IL-33 injections began and were administered at the same time as CsA injections. Daily IL-33 therapy prevented the CsA-induced development of hypertension ( Figure 1A ), endothelial dysfunction ( Figure 1B and 1C) , and vascular ( Figure 1D ) and renal injury ( Figure 1D and 1E). IL-33 treatment also normalized serum creatinine levels (Con=0.7014±0.0794, Con+IL-33=0.3263±0.2376, CsA=1.4174±0.0207, CsA+IL-33=0.7964±0.0517; CsA P<0.05 versus Con). These beneficial effects were associated with a significant increase in MDSC levels ( Figure 1F ; Figure  S2 ).
Adoptive Transfer of MDSCs Ameliorates CsA-Induced Hypertension and Vascular and Renal Injury
To determine whether MDSCs could reduce blood pressure after mice were already hypertensive (treatment study), we performed adoptive transfer of MDSCs on days 1, 4, and 7 after CsA injections. MDSC adoptive transfer dosedependently decreased systolic blood pressure (Figure 2A) . Injections of 1 million MDSCs partially lowered systolic blood pressure, whereas injections of 2 million MDSCs completely normalized systolic blood pressure. One million MDSCs partially improved aortic relaxation responses to acetylcholine in CsA-treated mice (data not shown), whereas 2 million MDSCs restored relaxation responses to control levels ( Figure 2B ). There were no effects on sodium nitroprussideinduced relaxation responses ( Figure 2C ). There was a dosedependent decrease in aortic fibronectin levels with 2 million MDSCs completely inhibiting the CsA-induced increase ( Figure 2D ). The same dose-dependent effects were observed for glomerular injury ( Figure 2E ). Adoptive transfer of 2 million MDSCs had no effect on splenic Treg levels, which remained decreased in CsA-treated mice ( Figure 2F ). The gating strategy for flow cytometry analysis of splenic Tregs is presented in Figure S1 .
MDSCs Prevent the Direct Vascular, Renal, and Endothelial Cell Effects of CsA
Incubation of isolated aortas from control mice with CsA for 24 hours caused a significant decrease in acetylcholine-mediated relaxation responses and this was improved partially by the presence of MDSCs ( Figure 3A) . In these aortas, CsA significantly increased levels of the inflammation marker E-selectin and this was prevented completely by the presence of MDSCs ( Figure 3B ). Incubation of isolated kidneys obtained from control mice with CsA for 24 hours significantly increased fibronectin levels and this was prevented by the presence of MDSCs ( Figure 3C ). Last, CsA treatment of microvascular and glomerular endothelial cells for 24 hours significantly increased fibronectin levels and this was prevented completely by the presence of MDSCs ( Figure 3D ).
Inhibition of Calcineurin Decreases MDSCs
To first demonstrate that MDSCs may be directly affected by the calcineurin inhibitor CsA, we isolated MDSCs from the spleens and bone marrow from different control mice and measured calcineurin protein levels by immunoblotting. MDSCs do contain calcineurin ( Figure 4A ). Next, we treated isolated MDSCs with increasing concentrations of CsA for Aortic relaxation responses to acetylcholine (B) and sodium nitroprusside (C) after contraction to phenylephrine were measured on day 8 after euthanization. D, Aortic fibronectin levels were measured by immunoblotting and normalized to the loading control actin. E, Representative glomeruli and glomerular injury index score for each group. F, Splenic regulatory T cell levels as determined by flow cytometry. Results are expressed as mean+SEM. *P<0.05 vs Con and n=6 to 8 mice in each group. There were no significant group×treatment interactions as determined by 2-way ANOVA or repeated measures 2-way ANOVA.
24 hours and found that the number of live MDSC numbers were decreased significantly in a dose-dependent manner ( Figure 4B ). The same experiments were also performed with varying concentrations of the calcineurin autoinhibitory peptide and the selective NFAT inhibitor VIVIT. Both calcineurin autoinhibitory peptide and VIVIT dose-dependently decreased the numbers of live MDSCs when compared with DMSO vehicle-treated MDSCs ( Figure 4C and 4D ).
Discussion
CsA remains in clinical use despite the known detrimental cardiovascular and renal side effects, as well as its negative effects on Tregs. CsA inhibits the calcium-dependent phosphatase calcineurin, which prevents dephosphorylation and nuclear translocation of NFAT, and NFAT-mediated transcription of self-proliferation signals, which is how it suppresses T cells. Whether this mechanism also occurs in MDSCs leading to their reduction in CsA-induced hypertension, or whether MDSCs increase in a compensatory manner like in other experimental models of hypertension, 27 was unknown. Additionally, we wanted to determine whether augmenting MDSCs could ameliorate CsA-induced vascular and renal injury and hypertension. The main findings of the current study are that the treatment with either IL-33 or MDSCs was able to eradicate hypertension, endothelial dysfunction, and vascular and glomerular injury caused by CsA in mice and that direct calcineurin inhibition decreases MDSC levels.
MDSCs exert beneficial effects in many inflammatory and autoimmune diseases including atherosclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease, alopecia, and Type 1 diabetes mellitus. [17] [18] [19] 23, 24, [36] [37] [38] [39] [40] [41] [42] In the current study, MDSC augmentation through 2 different strategies, either IL-33 therapy or MDSC adoptive transfer, ameliorated the CsA-induced hypertension and vascular and renal injury A, Aortas were isolated from control (Con) mice and incubated with DMSO-saline vehicle (Con) or cyclosporine A (CsA) for 24 h in the absence and presence of 75 000 MDSCs isolated from control mice and then relaxation responses to acetylcholine were measured after contraction with phenylephrine. B, The rest of the aortic tissue from above was used to measure e-selectin levels by immunoblotting and normalized to the loading control actin. C, Right kidneys were isolated from control mice and incubated with DMSO-saline vehicle (Con) or CsA for 24 h in the absence and presence of 75 000 MDSCs isolated from control mice. Fibronectin levels were then measured by immunoblotting and normalized to the loading control actin. D, Cultured microvascular and glomerular endothelial cells (ECs) were treated with DMSOsaline vehicle (Con) or CsA in the absence and presence of 75 000 MDSCs isolated from control mice and fibronectin levels were measured by immunoblotting and normalized to the loading control actin. *P<0.05 vs Con. There were no significant group×treatment interactions as determined by 2-way ANOVA.
similarly. One potential mechanism is through the induction of Tregs, as both IL-33 and MDSCs directly have been reported to increase Treg levels. 24, 25, 29 However, given the known negative effects of CsA on Treg levels, it was unknown how Treg levels would change in the setting of both MDSC augmentation and CsA. Here, we demonstrate that increased MDSC levels by adoptive transfer exerted their beneficial effects independent of Tregs, as their levels remained decreased.
Another new finding is that MDSCs exhibit direct organ and cellular protective effects. Aortas and kidneys isolated from control mice and then treated with CsA demonstrated vascular dysfunction, inflammation, and injury. It is noted that although there are increased aortic fibronectin levels in CsA-hypertensive mice, only endothelium-dependent relaxation responses are mitigated. This is likely because of the relatively short period of CsA-treatment for 1 week, whereas chronic administration for months would likely lead to major fibrosis and smooth muscle dysfunction. Additionally, microvascular and glomerular endothelial cells treated with CsA also exhibit injury as measured by increased fibronectin levels. The presence of MDSCs was able to completely block these CsA-induced effects in both organs and cells. Given the lack of immune cell infiltration during CsA treatment in these experiments, the mechanism likely includes the known ability of MDSCs to secrete the anti-inflammatory cytokines IL-4, IL-10, IL-13, and other factors. 17, 25, 26 These anti-inflammatory cytokines have been reported to reduce vascular injury and blood pressure in various models. [43] [44] [45] [46] [47] [48] [49] [50] Although measures of media levels of these cytokines in the current study may be helpful, we would not be able to identify the cellular source because endothelial cells can produce and secrete anti-inflammatory cytokines as well. Studies are underway to systematically determine which cytokine, or more likely cytokines, mediate the direct vascular and renal protective effects of MDSCs during CsA treatment. MDSCs lacking these anti-inflammatory cytokines either alone or in combination (ie, via knockdown or isolated from cytokine knockout mice) will be determined whether they lose their ex vivo and in vitro protective effects. The cytokine(s) that are determined to play a major role in the beneficial MDSC effects will be tested in CsA-hypertensive mice. We would hypothesize that MDSCs lacking the crucial antiinflammatory cytokine(s) would have no beneficial effects in CsA-treated mice.
In addition to the direct anti-inflammatory organ and cellular effects, in vivo, the known ability of MDSCs to reduce T cells likely also contributed to the blood pressure reduction because calcineurin inhibitors are known to increase proinflammatory T cells despite an overall reduction in total T cells. 9, 32 The beneficial blood pressure effects of MDSCs align with previous results from Shah et al 27 who demonstrated that adoptive transfer of MDSCs from hypertensive mice into angiotensin II-treated hypertensive mice 1 day before starting the angiotensin II infusion and 2 days later prevented the development of hypertension. Additionally, weekly treatment with MDSCs after angiotensin II-induced hypertension was established was able to normalize blood pressure. Further demonstrating their beneficial effects during hypertension, they reported that depletion of MDSCs worsened the angiotensin II-induced hypertensive phenotype. Given the strong antihypertensive effects of MDSCs, it is promising that autologous cell therapy with MDSCs may be feasible soon because groups are generating MDSCs from various cells including mouse embryonic stem cells and hematopoietic stem cells, as well as human peripheral blood mononuclear cells. 42, 51 We demonstrate that CsA-induced hypertension is associated with a decrease in MDSCs, unlike other forms of hypertension that are associated with a compensatory increase in peripheral levels of MDSCs. 27 Hypertension in mice induced by angiotensin II infusion, NOS inhibition, or high salt diet were all associated with increased levels of circulating MDSCs, which were reported to take on an immature and immunosuppressive phenotype. This increase in MDSCs was time-dependent and blood pressure-dependent. The authors determined that MDSCs in these forms of hypertension did not use iNOS or arginase to mediate their immunosuppressive activity but rather NADPH (nicotinamide adenine dinucleotide phosphate) oxidase-derived hydrogen peroxide killing of T cells. It was not determined whether there were direct vascular or renal anti-inflammatory effects in these models independent of T cell reduction.
The reduction of MDSC levels caused by CsA is likely because of the inhibition of the calcineurin/NFAT pathway as 2 other inhibitors of this pathway, calcineurin autoinhibitory peptide and VIVIT, dose-dependently decreased live MDSCs. The transcription factor NFAT has been reported to work together with the cell fate transcription factor family CCAAT-enhancer binding proteins (C/EBP) to form a composite enhancer complex. 52 Shah et al 27 reported an increase in C/EBP-β expression, which is crucial for MDSC formation, 53 in MDSCs from angiotensin II-induced hypertensive mice. They also reported decreased expression of C/EBP-α, which induces myeloid differentiation, in MDSCs from hypertensive mice. A previous study demonstrated that NFAT and C/ EBP can both bind a specific promoter in cells of the monocyte and macrophage lineage only and not in cells of a T-cell origin. 54 Additionally, CsA-mediated inhibition of calcineurin/NFAT increased C/EBP-α binding, which in the case of MDSCs would cause their differentiation into monocytes and macrophages. This may explain why CsA decreases MDSC levels instead of MDSC levels increasing as in other forms of hypertension.
Limitations of the current study include the blood pressure measures, lack of MDSC subset characterization and surface markers, and indirect IL-33 effects. We acknowledge that tail-cuff blood pressure measures are not as accurate as telemetry and every effort was made to acclimate the mice to the procedure which was performed at the same time of day. Tail-cuff measures were utilized to confirm that CsA-induced hypertension and to test whether IL-33 or MDSC adoptive transfer attenuated the hypertension. Future studies using direct measures of blood pressure can confirm these effects, as well as examine diurnal changes. Shah et al 27 reported that MDSCs that increase during hypertension in mice are both granulocytic and monocytic but that granulocytic MDSCs are more prevalent. Additionally, IL-33 affects many different cell types. 55 A recent article reported that IL-33 treatment in mice expanded anti-inflammatory type 2 innate lymphoid cells in the kidneys and this protected against adriamycin-induced glomerulosclerosis. Also, IL-33 has been reported to increase Tregs in addition to MDSCs, 28, 29 but the role of Tregs in the beneficial effects of IL-33 treatment in CsA-treated mice was not assessed, although they did not increase after MDSC adoptive transfer. Last, we did not assess where the injected MDSCs localized to, but Shah et al 27 reported that injected MDSCs traffic to the kidney and spleen in hypertensive mice. Studies are underway to determine whether they infiltrate blood vessels and kidneys or remain in the circulation in the setting of CsA-induced hypertension. Nonetheless, augmenting MDSCs had direct protective cardiovascular and renal effects against CsA-induced injury.
In conclusion, the direct inhibition of calcineurin/NFAT in MDSCs reduces their numbers and this loss of MDSCs and their anti-inflammatory effects contribute to the development of CsA-induced toxicity and hypertension. Augmenting MDSCs reduces the detrimental cardiovascular and renal effects of CsA in mice and may be a therapeutic strategy for CsA-treated patients.
Perspectives
CsA inhibition of calcineurin in MDSCs decreases their numbers, and the reduction of MDSC anti-inflammatory effects contributes to the development of vascular and renal toxicity and hypertension. Increasing MDSC levels reduces the organ injury and hypertension caused by CsA.
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